Observational Study of Trastuzumab Deruxtecan for HER2-Positive Cancers
This study is looking at how well a drug called trastuzumab deruxtecan works in people with certain advanced cancers that have a specific marker called HER2 (IHC 3+). These cancers include adenocarcinoma, anal, bladder, cervical, and endometrial cancers. You might be able to join if you've already had other treatments and your doctor believes there are no other good options. The study wants to see how many people respond to the treatment and for how long. The study is currently unclear on its recruitment status and plans to enroll about 100 people.
- Study design
- This is an observational study, meaning researchers will watch how the treatment works in real-world settings. About 100 people will be included.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be followed for up to 2.5 years after you join the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
DESTINY-PANTUMOUR04
At a glance
Conditions
Where it's being run
18 sites across 13 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Real world response rate (rwRR)Through study completion, up to 2.5 years after enrolment
rwRR is defined as the proportion of patients with a clinician assessment of complete or partial response while on T-DXd treatment
- Real world duration of response (rwDoR)Through study completion, up to 2.5 years after enrolment
rwDoR is defined as the time from first physician reported complete or partial response until time of progression or death